Tissue Inhibitor of Metalloproteinase (TIMP)-2 Acts Synergistically with Synthetic Matrix Metalloproteinase (MMP) Inhibitors but Not with TIMP-4 to Enhance the (Membrane Type 1)-MMP-dependent Activation of Pro-MMP-2*

The membrane-type 1 matrix metalloproteinase (MT1-MMP) has been shown to be a key enzyme in tumor angiogenesis and metastasis. MT1-MMP hydrolyzes a variety of extracellular matrix components and is a physiological activator of pro-MMP-2, another MMP involved in malignancy. Pro-MMP-2 activation by MT1-MMP involves the formation of an MT1-MMP·tissue inhibitors of metalloproteinases 2 (TIMP-2)·pro-MMP-2 complex on the cell surface that promotes the hydrolysis of pro-MMP-2 by a neighboring TIMP-2-free MT1-MMP. The MT1-MMP·TIMP-2 complex also serves to reduce the intermolecular autocatalytic turnover of MT1-MMP, resulting in accumulation of active MT1-MMP (57 kDa) on the cell surface. Evidence shown here inTimp2-null cells demonstrates that pro-MMP-2 activation by MT1-MMP requires TIMP-2. In contrast, a C-terminally deleted TIMP-2 (Δ-TIMP-2), unable to form ternary complex, had no effect. However, Δ-TIMP-2 and certain synthetic MMP inhibitors, which inhibit MT1-MMP autocatalysis, can act synergistically with TIMP-2 in the promotion of pro-MMP-2 activation by MT1-MMP. In contrast, TIMP-4, an efficient MT1-MMP inhibitor, had no synergistic effect. These studies suggest that under certain conditions the pericellular activity of MT1-MMP in the presence of TIMP-2 can be modulated by synthetic and natural (TIMP-4) MMP inhibitors.

• Publication year

  2000

• Venue

  Journal of Biological Chemistry

• Publication date

  2000-12-29

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1074/jbc.M006871200PMID 10998420
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors.

  2000cited by this paper
• Matrix metalloproteinases: biologic activity and clinical implications.

  2000cited by this paper
• Inactivating Mutation of the Mouse Tissue Inhibitor of Metalloproteinases-2(Timp-2) Gene Alters ProMMP-2 Activation*

  2000cited by this paper
• Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I.

  2000cited by this paper
• Regulation of Cell Invasion and Morphogenesis in a Three-Dimensional Type I Collagen Matrix by Membrane-Type Matrix Metalloproteinases 1, 2, and 3

  2000cited by this paper
• Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system.

  2000cited by this paper
• TIMP-2 Is Required for Efficient Activation of proMMP-2 in Vivo *

  2000cited by this paper
• Potent and Selective Mechanism-Based Inhibition of Gelatinases

  2000cited by this paper
• Characterization of the Monomeric and Dimeric Forms of Latent and Active Matrix Metalloproteinase-9

  2000cited by this paper
• Binding of Active (57 kDa) Membrane Type 1-Matrix Metalloproteinase (MT1-MMP) to Tissue Inhibitor of Metalloproteinase (TIMP)-2 Regulates MT1-MMP Processing and Pro-MMP-2 Activation*

  2000cited by this paper
• Membrane Type 1 Matrix Metalloproteinase-associated Degradation of Tissue Inhibitor of Metalloproteinase 2 in Human Tumor Cell Lines*

  2000cited by this paper
• Front-cell-specific expression of membrane-type 1 matrix metalloproteinase and gelatinase A during cohort migration of colon carcinoma cells induced by hepatocyte growth factor/scatter factor.

  2000cited by this paper
• Clinical studies with matrix metalloproteinase inhibitors

  1999cited by this paper
• Biophysical and Functional Characterization of Full-length, Recombinant Human Tissue Inhibitor of Metalloproteinases-2 (TIMP-2) Produced in Escherichia coli

  1999cited by this paper
• First Place—Resident Basic Science Award 1998: Role of Membrane Type 1-Matrix Metalloproteinase and Gelatinase a in Head and Neck Squamous Cell Carcinoma Invasion in Vitro

  1999cited by this paper
• MMP Inhibitors: Experimental and Clinical Studies

  1999cited by this paper
• MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover.

  1999cited by this paper
• Marimastat (BB2516): Current status of development

  1999cited by this paper
• Leukolysin/MMP25/MT6-MMP: a novel matrix metalloproteinase specifically expressed in the leukocyte lineage

  1999cited by this paper
• Identification and Characterization of the Fifth Membrane-type Matrix Metalloproteinase MT5-MMP*

  1999cited by this paper
• Matrix metalloproteinases and metastasis

  1999cited by this paper
• Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.

  1999cited by this paper
• Clinical Potential of Matrix Metalloprotease Inhibitors

  1999cited by this paper
• Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention.

  1999cited by this paper
• Expression of MMPS, MT‐MMP, and TIMPs in squamous cell carcinoma of the oral cavity: Correlations with tumor invasion and metastasis

  1999cited by this paper
• Expression of MMP‐2 and MMP‐9, their inhibitors, and the activator MT1‐MMP in primary breast carcinomas

  1999cited by this paper
• MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma--a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization.

  1999cited by this paper
• The Next Generation of MMP Inhibitors: Design and Synthesis

  1999cited by this paper
• Identification of the TIMP‐2 Binding Site on the Gelatinase A Hemopexin C‐Domain by Site‐Directed Mutagenesis and the Yeast Two‐Hybrid System

  1999cited by this paper
• Matrix Metalloproteinases*

  1999cited by this paper
• Transformation of epithelial Madin-Darby canine kidney cells with p60(v-src) induces expression of membrane-type 1 matrix metalloproteinase and invasiveness.

  1998cited by this paper
• Matrix metalloproteinases: structures, evolution, and diversification

  1998cited by this paper
• The activation of ProMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form.

  1998cited by this paper
• Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) Binds to the Catalytic Domain of the Cell Surface Receptor, Membrane Type 1-Matrix Metalloproteinase 1 (MT1-MMP)*

  1998cited by this paper
• MT1‐MMP on the cell surface causes focal degradation of gelatin films

  1998cited by this paper
• Membrane-type matrix metalloproteinase-1(MT1-MTP) gene is overexpressed in highly invasive hepatocellular carcinomas.

  1998cited by this paper
• Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human urothelial carcinomas.

  1998cited by this paper
• Prognostic values of matrix metalloproteinase‐2 and tissue inhibitor of metalloproteinase‐2 expression in bladder cancer

  1998cited by this paper
• Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.

  1998cited by this paper
• Immunological characterization of cell‐surface and soluble forms of membrane type 1 matrix metalloproteinase in human breast cancer cells and in fibroblasts

  1998cited by this paper
• The TIMP2 Membrane Type 1 Metalloproteinase “Receptor” Regulates the Concentration and Efficient Activation of Progelatinase A

  1998cited by this paper
• Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.

  1998cited by this paper
• Crystal structure of the complex formed by the membrane type 1‐matrix metalloproteinase with the tissue inhibitor of metalloproteinases‐2, the soluble progelatinase A receptor

  1998cited by this paper
• Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins.

  1998cited by this paper
• Phorbol ester-induced cell surface association of matrix metalloproteinase-9 in human MCF10A breast epithelial cells.

  1997cited by this paper
• Kinetic Analysis of the Binding of Human Matrix Metalloproteinase-2 and -9 to Tissue Inhibitor of Metalloproteinase (TIMP)-1 and TIMP-2*

  1997cited by this paper
• Matrix metalloproteinase inhibitors in the treatment of cancer

  1997cited by this paper
• Increased expression of membrane type 1‐matrix metalloproteinase in head and neck carcinoma

  1997cited by this paper
• High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases.

  1997cited by this paper
• The C-terminal domain of tissue inhibitor of metalloproteinases-2 is required for cell binding but not for antimetalloproteinase activity.

  1997cited by this paper
• Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases.

  1997cited by this paper
• Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion.

  1997cited by this paper
• Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas.

  1997cited by this paper
• Specific, High Affinity Binding of Tissue Inhibitor of Metalloproteinases-4 (TIMP-4) to the COOH-terminal Hemopexin-like Domain of Human Gelatinase A

  1997cited by this paper
• Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat.

  1997cited by this paper
• Matrix Metalloproteinases

  1997cited by this paper
• Membrane Type 1 Matrix Metalloproteinase Digests Interstitial Collagens and Other Extracellular Matrix Macromolecules*

  1997cited by this paper
• Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay.

  1996cited by this paper
• Targeted mutagenesis of Timp-1 reveals that lung tumor invasion is influenced by Timp-1 genotype of the tumor but not by that of the host.

  1996cited by this paper
• Transmembrane-deletion Mutants of the Membrane-type Matrix Metalloproteinase-1 Process Progelatinase A and Express Intrinsic Matrix-degrading Activity (*)

  1996cited by this paper
• Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma.

  1996cited by this paper
• The recombinant catalytic domain of membrane‐type matrix metalloproteinase‐1 (MT1‐MMP) induces activation of progelatinase A and progelatinase A complexed with TIMP‐2

  1996cited by this paper
• The Soluble Catalytic Domain of Membrane Type 1 Matrix Metalloproteinase Cleaves the Propeptide of Progelatinase A and Initiates Autoproteolytic Activation

  1996cited by this paper
• Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors.

  1996cited by this paper
• Carbohydrate-mediated regulation of matrix metalloproteinase-2 activation in normal human fibroblasts and fibrosarcoma cells.

  1996cited by this paper
• Mechanism Of Cell Surface Activation Of 72-kDa Type IV Collagenase

  1995cited by this paper
• Fluorimetric assays of proteolytic enzymes.

  1995cited by this paper
• Identification of the Second Membrane-type Matrix Metalloproteinase (MT-MMP-2) Gene from a Human Placenta cDNA Library

  1995cited by this paper
• [2] Fluorimetric assays of proteolytic enzymes

  1995cited by this paper
• A matrix metalloproteinase expressed on the surface of invasive tumour cells

  1994cited by this paper
• Enhanced expression of tissue inhibitor of metalloproteinase‐2 (TIMP‐2) in the stroma of breast carcinomas correlates with tumor recurrence

  1994cited by this paper
• Immunohistochemical localization of matrix metallloproteinase 2 and its specific inhibitor timp‐2 in neoplastic tissues with monclonal antibodies

  1994cited by this paper
• Matrix metalloproteinases: a review.

  1993cited by this paper
• Expression of human recombinant 72 kDa gelatinase and tissue inhibitor of metalloproteinase-2 (TIMP-2): characterization of complex and free enzyme.

  1993cited by this paper
• Slow-binding inhibition of NAD+ glycohydrolase by arabino analogues of beta-NAD.

  1992cited by this paper
• Production of homozygous mutant ES cells with a single targeting construct

  1992cited by this paper
• Domain structure of human 72-kDa gelatinase/type IV collagenase. Characterization of proteolytic activity and identification of the tissue inhibitor of metalloproteinase-2 (TIMP-2) binding regions.

  1992cited by this paper
• Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.

  1991cited by this paper
• Concanavalin A produces a matrix-degradative phenotype in human fibroblasts. Induction and endogenous activation of collagenase, 72-kDa gelatinase, and Pump-1 is accompanied by the suppression of the tissue inhibitor of matrix metalloproteinases.

  1990cited by this paper
• Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes

  1987cited by this paper
• Enzyme kinetics

  1975cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper

• Mathematical modelling of the contribution of senescent fibroblasts to basement membrane digestion during carcinoma invasion

  2026cites this paper
• Interleukin-1β activates matrix metalloproteinase-2 to alter lacrimal gland myoepithelial cell structure and function

  2024cites this paper
• Matrix metalloproteinases as biomarkers and therapeutic targets in colitis-associated cancer

  2024cites this paper
• Collagenases and their inhibitors: a review

  2023cites this paper
• Reviving the use of inhibitors of matrix metalloproteases in spinal cord injury: a case for specificity

  2023cites this paper
• MMP8 increases tongue carcinoma cell–cell adhesion and diminishes migration via cleavage of anti-adhesive FXYD5

  2021cites this paper
• TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells

  2020cites this paper
• XCL1‐XCR1 pathway promotes trophoblast invasion at maternal‐fetal interface by inducing MMP‐2/MMP‐9 activity

  2018cites this paper
• Temozolomide does not influence the transcription or activity of matrix metalloproteinases 9 and 2 in glioma cell lines.

  2017cites this paper
• Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

  2017cites this paper
• Acute Genotoxic Stress-Induced Senescence in Human Mesenchymal Cells Drives a Unique Composition of Senescence Messaging Secretome (SMS)

  2017cites this paper
• Selective small-molecule inhibitors as chemical tools to define the roles of matrix metalloproteinases in disease.

  2017cites this paper
• Expression and Activity of Metalloproteinases in Depression

  2016cites this paper
• Does Loss of LEKTI Expression Correlate with Increased Perineural Invasion in Squamous Cell Carcinoma of the Skin ?

  2016cites this paper
• Glioblastoma multiforme targeted therapy: The Chlorotoxin story.

  2016cites this paper
• Molecular and Biochemical Properties of Lympho- Epithelial Kazal-Type-Inhibitor (LEKTI)

  2015cites this paper
• Lipid-Soluble Ginseng Extract Inhibits Invasion and Metastasis of B16F10 Melanoma Cells

  2015cites this paper
• Low-dose UVB irradiation prevents MMP2-induced skin hyperplasia by inhibiting inflammation and ROS.

  2015influential citation
• Mathematical modelling of cancer growth and spread : the role of matrix metalloproteinases

  2015cites this paper
• Mechanisms of proteolytic activity regulation exerted via a unique propeptide in matrix metalloproteinases and intra/intermolecular interactions in a novel family of minimal gluzincins

  2015cites this paper
• Expression of LEKTI correlates with PNI and LVI in SCC of the oral tongue and mechanism of LEKTI loss in HNSCC

  2015cites this paper
• Tissue Inhibitors of Metalloproteinases (TIMPs): Inhibition of Zn‐Dependent Metallopeptidases

  2014cites this paper
• EGFR and HER2 exert distinct roles on colon cancer cell functional properties and expression of matrix macromolecules.

  2014cites this paper
• siRNA knockdown of tissue inhibitor of metalloproteinase-1 in keloid fibroblasts leads to degradation of collagen type I.

  2014cites this paper
• The emerging role of MMP14 in brain tumorigenesis and future therapeutics.

  2014influential citation
• Current Status of LEKTI, a Physiological Inhibitor of Multiple Proteinases in the Skin - A Review

  2014cites this paper
• The Matrix Metalloproteinase Inhibitor Marimastat Promotes Neural Progenitor Cell Differentiation into Neurons by Gelatinase-Independent TIMP-2-Dependent Mechanisms

  2013cites this paper
• Mathematical Modeling of Cancer Invasion: The Role of Membrane-Bound Matrix Metalloproteinases

  2013cites this paper
• Glioma Xenograft Growth and Angiogenesis Membrane-type 1 Matrix Metalloproteinase Stimulates Human Up-Regulation of Vascular Endothelial Growth Factor by

  2013cites this paper
• Selective Inhibition of Matrix Metalloproteinase-9 Attenuates Secondary Damage Resulting from Severe Traumatic Brain Injury

  2013cites this paper
• VEGF Secreted by Hypoxic Müller Cells Induces MMP-2 Expression and Activity in Endothelial Cells to Promote Retinal Neovascularization in Proliferative Diabetic Retinopathy

  2013influential citation
• Microfabricated collagen tracks facilitate single cell metastatic invasion in 3D.

  2013cites this paper
• Clinical Relevance of Matrix Metalloproteases and their Inhibitors in Breast Cancer

  2013cites this paper
• Regulation of MT1-MMP Activation and Its Relevance to Disease Processes

  2013cites this paper
• Matrix Metalloproteinase Inhibitors

  2012cites this paper
• Establishment and Validation of Computational Model for MT1-MMP Dependent ECM Degradation and Intervention Strategies

  2012cites this paper
• Filamin A controls matrix metalloproteinase activity and regulates cell invasion in human fibrosarcoma cells

  2012cites this paper
• Regulation of Metalloproteinase-dependent Ectodomain Shedding in Cytokine Biology and Inflammation

  2012cites this paper
• Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

  2012cites this paper
• Metastasis Research Protocols

  2012cites this paper
• Control and inhibition analysis of complex formation processes

  2012cites this paper
• Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography.

  2012cites this paper
• Immunohistochemical evaluation of MMP-2 and TIMP-2 in canine mammary tumours: a survival study.

  2011cites this paper
• Role of Matrix Metalloproteinases and Therapeutic Benefits of Their Inhibition in Spinal Cord Injury

  2011cites this paper
• Reduced NO signaling during pregnancy attenuates outward uterine artery remodeling by altering MMP expression and collagen and elastin deposition.

  2011cites this paper
• Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting

  2011cites this paper
• Vascular Protective Role of Vitexicarpin Isolated from Vitex rotundifolia in Human Umbilical Vein Endothelial Cells

  2011cites this paper
• Looking at the proteases from a simple perspective

  2011cites this paper
• Sulfonate-containing thiiranes as selective gelatinase inhibitors.

  2011cites this paper
• Endogenous matrix metalloproteinases 2 and 9 regulate activation of CD4+ and CD8+ T cells.

  2011cites this paper
• To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition.

  2010cites this paper
• Coordinate action of membrane‐type matrix metalloproteinase‐1 (MT1‐MMP) and MMP‐2 enhances pericellular proteolysis and invasion

  2010cites this paper
• Protective role of betulinic acid on TNF-alpha-induced cell adhesion molecules in vascular endothelial cells.

  2010cites this paper
• Non-apoptotic Fas signaling regulates invasiveness of glioma cells and modulates MMP-2 activity via NFkappaB-TIMP-2 pathway.

  2010cites this paper
• Proteases as anti-cancer targets--molecular and biological basis for development of inhibitor-like drugs against cancer.

  2009cites this paper
• STRUCTURAL INTERACTIONS BETWEEN THE Α3Β1 INTEGRIN AND MMP-2: A POTENTIAL FUNCTIONAL ROLE IN CELL ADHESION

  2009cites this paper
• TIMPs: Extracellular Modifiers in Cancer Development

  2008cites this paper
• Activation and silencing of matrix metalloproteinases.

  2008cites this paper
• The Inactive 44-kDa Processed Form of Membrane Type 1 Matrix Metalloproteinase (MT1-MMP) Enhances Proteolytic Activity via Regulation of Endocytosis of Active MT1-MMP*

  2008cites this paper
• Control of matrix metalloproteinase catalytic activity.

  2007cites this paper
• Metastasis‐related factors expressed in pT1 pN0 breast cancer: Assessment of recurrence risk

  2007cites this paper
• Neutrophil Elastase Up-Regulates Cathepsin B and Matrix Metalloprotease-2 Expression1

  2007cites this paper
• Neutrophil Elastase UpRegulates Cathepsin B and Matrix Metalloprotease-2 Expression 1

  2007cites this paper
• Substrate choice of membrane‐type 1 matrix metalloproteinase is dictated by tissue inhibitor of metalloproteinase‐2 levels

  2007cites this paper
• Monoamine oxydases et athérosclérose : signalisation mitogène et étude in vivo

  2007cites this paper
• Activation-coupled membrane-type 1 matrix metalloproteinase membrane trafficking.

  2007cites this paper
• Metabolism of a Highly Selective Gelatinase Inhibitor Generates Active Metabolite

  2007cites this paper
• Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation★

  2006cites this paper
• Vascular endothelial growth factor–regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases

  2006cites this paper
• Human melanoma cells release soluble and functional receptors.

  2006cites this paper
• MMPs--role in cardiovascular development and disease.

  2006cites this paper
• The enzymatic pathway of MMP2 is involved in synaptic remodeling induced by axotomy of rat superior cervical ganglion neurons

  2006cites this paper
• The Effects of Tumor Necrosis Factor-α, Interleukin-1β, Interleukin-6, and Transforming Growth Factor-β1 on Pulp Fibroblast Mediated Collagen Degradation

  2006cites this paper
• The effects of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and transforming growth factor-beta1 on pulp fibroblast mediated collagen degradation.

  2006cites this paper
• Expression of membrane type 1 matrix metalloproteinase is associated with cervical carcinoma progression and invasion.

  2005cites this paper
• Synthesis, quality control and in vivo evaluation of [I-123] rhTIMP-2, a potential tumour-imaging agent

  2005cites this paper
• Palmitoylation at Cys574 is essential for MT1‐MMP to promote cell migration

  2005cites this paper
• Respostas celulares aos danos causados pelo antitumoral cisplatina em linhagens de fibroblastos humanos normais (MRC-5) e astrocítica (U343 MG-a).

  2005cites this paper
• Mutational and Structural Analyses of the Hinge Region of Membrane Type 1-Matrix Metalloproteinase and Enzyme Processing*

  2005cites this paper
• Cleavage at the stem region releases an active ectodomain of the membrane type 1 matrix metalloproteinase.

  2005cites this paper
• TIMP3 mutation in Sorsby's fundus dystrophy: molecular insights

  2005cites this paper
• Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix metalloproteinases.

  2005cites this paper
• Membrane type-matrix metalloproteinases and tumor progression.

  2005cites this paper
• Potent Mechanism-based Inhibitors for Matrix Metalloproteinases*

  2005cites this paper
• The transmembrane domain is essential for the microtubular trafficking of membrane type-1 matrix metalloproteinase (MT1-MMP)

  2005cites this paper
• Two separate metalloproteinase activities are responsible for the shedding and processing of the NG2 proteoglycan in vitro.

  2005cites this paper
• Matrix metalloproteinase inhibitor RECK expression in canine tumors.

  2005cites this paper
• Tissue inhibitor of metalloproteinase‐2 (TIMP‐2) expression during cardiac neural crest cell migration and its role in proMMP‐2 activation

  2004cites this paper
• Matrix metalloproteinases and colon anastomosis repair: a new indication for pharmacological inhibition?

  2004cites this paper
• Endoproteolytic Activation of &agr;v Integrin by Proprotein Convertase PC5 Is Required for Vascular Smooth Muscle Cell Adhesion to Vitronectin and Integrin-Dependent Signaling

  2004cites this paper
• Glycosylation Broadens the Substrate Profile of Membrane Type 1 Matrix Metalloproteinase*

  2004cites this paper
• Group IB Secretory Phospholipase A2 Promotes Matrix Metalloproteinase-2-mediated Cell Migration via the Phosphatidylinositol 3-Kinase and Akt Pathway*

  2004cites this paper
• Membrane Type 1-Matrix Metalloproteinase (MMP)-Associated MMP-2 Activation Increases in the Rat Ovary in Response to an Ovulatory Dose of Human Chorionic Gonadotropin1

  2004cites this paper
• A Theoretical Model of Type I Collagen Proteolysis by Matrix Metalloproteinase (MMP) 2 and Membrane Type 1 MMP in the Presence of Tissue Inhibitor of Metalloproteinase 2*[boxs]

  2004cites this paper
• Processing, shedding, and endocytosis of membrane type 1‐matrix metalloproteinase (MT1‐MMP)

  2004cites this paper
• Proprotein convertases regulate insulin-like growth factor 1-induced membrane-type 1 matrix metalloproteinase in VSMCs via endoproteolytic activation of the insulin-like growth factor-1 receptor.

  2004cites this paper
• The Hemopexin Domain of Membrane-type Matrix Metalloproteinase-1 (MT1-MMP) Is Not Required for Its Activation of proMMP2 on Cell Surface but Is Essential for MT1-MMP-mediated Invasion in Three-dimensional Type I Collagen*

  2004cites this paper
• Differential Inhibition of Membrane Type 3 (MT3)-Matrix Metalloproteinase (MMP) and MT1-MMP by Tissue Inhibitor of Metalloproteinase (TIMP)-2 and TIMP-3 Regulates Pro-MMP-2 Activation*

  2004cites this paper
• Dual Regulation of MMP-2 Expression by the Type 1 Insulin-like Growth Factor Receptor

  2004cites this paper
• Purification and characterization of major gelatin-cleavage activities in the apically located extracellular matrix of the sea urchin embryo

  2004cites this paper